Sotoracib (AMG510) latest price in 2023

Sotoraxib (AMG510) is a new type of targeted therapy that is used to treat certain types of cancer, especially those carrying the KRAS G12C mutation. The development of this drug marks a breakthrough for a type of cancer long considered difficult to treat. KRAS G12CMutation is a common mutation in many cancers, including lung cancer and colorectal cancer.

However, sotorasibu has not yet received marketing approval in China, so domestic patients cannot purchase it directly. However, they can obtain the drug overseas. In overseas markets, sotorasibu is divided into two types: original drugs and generic drugs. The original drugs mainly include the European version and the Hong Kong version, which are quite expensive, generally in the range of hundreds of thousands of yuan. This price is undoubtedly a huge financial burden for most patients.

Relatively speaking, the prices of generic drugs that have been launched abroad are more affordable. Take generic drugs in Laos as an example. Recently, the prices of generic drugs produced by Lao Lucius and Lao Daxiong companies have been significantly reduced, and now only cost more than one thousand to more than two thousand yuan. Such a price greatly reduces the financial pressure on patients, making it affordable for more patients who need this drug.

It is worth noting that although there is a huge difference in price between original drugs and generic drugs, their ingredients are basically the same. Therefore, patients can consider price more when making choices without having to worry too much about drug quality.

In general, as a targeted therapy drug, sotoracib is not yet available in China, but patients can still obtain it through overseas channels. Although the original drugs are expensive, the generic drugs that have been launched overseas are relatively affordable, which alleviates a lot of financial pressure on patients who need treatment and brings hope.